Allergic Asthma, Perennial Allergic Rhinoconjunctivitis
Conditions
Brief summary
The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.
Interventions
BIOLOGICALCYT005-AllQbG10
Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
Sponsors
Cytos Biotechnology AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites * Mild asthma * Females only if non-reproductive or agree to practice an effective and accepted method of contraception
Exclusion criteria
* Relevant cardiovascular, renal, pulmonary or endocrine disease * History of autoimmune disease * Severe allergies * History of active infectious disease * Current diagnosis or history of malignancy * Relevant neurological or psychiatric disorder * Pregnancy or lactation * History of alcohol abuse or other recreational drugs * Use of an investigational drug within three month before enrolment * Blood donation within 30 days before enrolment
Countries
Switzerland
Outcome results
None listed